Ex­clu­sive: Col­umn Group rais­es a new $400M+ fund and R&D hub for sin­gle-as­set bi­o­log­ics com­pa­nies

As the biotech in­dus­try grap­ples with how to fund drug de­vel­op­ment in a world of in­creas­ing re­search costs, ris­ing drug prices and gov­ern­ment-re­lat­ed risk, a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER